此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

远程监测平台“CUREETY TECHCARE”与开始一线治疗的 mTBNC 患者的护理标准对比 (ALTERNATIVE)

2026年9月24日 更新者:UNICANCER

一项随机 III 期研究,将数字远程监测平台“CUREETY TECHCARE”与开始一线系统治疗的三阴性转移性乳腺癌患者的常规护理标准进行比较

The goal of this clinical trial is to assess whether adding telemonitoring (the digital telemonitoring platform "CUREETY TECHCARE"), to standard care, will benefit patients with previously untreated metastatic triple-negative breast cancer starting first-line cancer therapy.

The main questions it aims to answer are:

  • Is patient quality of life improved by using the telemonitoring platform?
  • Are patients hospitalized less frequently when using the telemonitoring platform?
  • Is the patient overall survival improved by telemonitoring ?

Researchers will compare data from patients using telemonitoring while receiving standard care with data from patients receiving only standard care.

Participants using telemonitoring will answer questions about their symptoms on the platform. The platform will analyze these symptoms, assess the patient's general condition and provide advice accordingly. Medical staff will also access the platform to monitor the patient's general condition and contact them if necessary.

研究概览

地位

终止

研究类型

介入性

注册 (实际的)

31

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Arras、法国
        • Institut de Cancérologie des Hauts-de-France (ICHF)
      • Auxerre、法国
        • Centre Hospitalier d'Auxerre
      • Avignon、法国
        • Sainte Catherine - Institut du Cancer Avignon Provence
      • Bayeux、法国
        • CH Aunay-Bayeux
      • Beauvais、法国
        • Centre Hospitalier Simone Veil de Beauvais
      • Beuvry、法国
        • ICHF - Centre Pierre Curie
      • Blois、法国
        • Hôpital Simone Veil de Blois
      • Bordeaux、法国
        • Polyclinique bordeaux nord
      • Bourg-en-Bresse、法国
        • Centre Hospitalier Fleyriat
      • Caen、法国
        • Centre de Cancérologie Privé de Caen Maurice Tubiana
      • Caen、法国
        • Centre Francois Baclesse
      • Carcassonne、法国
        • Centre hospitalier de Carcasonne
      • Chambray-lès-Tours、法国
        • Recherche Oncologie Clinqiue 37 (ROC 37)
      • Cholet、法国
        • CH de Cholet
      • Colmar、法国
        • CH Colmar
      • Creil、法国
        • Groupe Hospitalier Public du Sud de l'Oise (GHPSO)
      • Dijon、法国
        • Centre Georges François Leclerc
      • Dunkirk、法国
        • Institut Andrée Dutreix
      • Fréjus、法国
        • Centre Hospitalier Intercommunal de Fréjus Saint Raphael
      • Grenoble、法国
        • Groupe Hospitalier Mutualiste de Grenoble
      • La Rochelle、法国
        • Groupe Hospitalier de La Rochelle-Ré-Aunis
      • La Réunion、法国
        • CHU de la réunion
      • La Réunion、法国
        • Clinique Sainte Clotilde
      • La Tronche、法国
        • CHU Grenoble Alpes
      • Le Coudray、法国
        • Centre Hospitalier Louis Pasteur
      • Le Mans、法国
        • Centre Hospitalier Le Mans
      • Le Puy-en-Velay、法国
        • Centre Hospitalier Emile Roux
      • Lorient、法国
        • GHBS Lorient
      • Lyon、法国
        • Clinique de la Sauvegarde
      • Lyon、法国
        • Centre Leon Berard
      • Lyon、法国
        • Hôpital Privé Jean Mermoz
      • Marseille、法国
        • Institut Paoli Calmettes
      • Mont-de-Marsan、法国
        • CHI de Mont-de-Marsan et du Pays des Sources
      • Montpellier、法国
        • Centre de Cancérologie du Grand Montpellier
      • Nantes、法国
        • Hôpital Privé du Confluent
      • Neuilly-sur-Seine、法国
        • Clinique Ambroise-Pare Hartmann
      • Neuilly-sur-Seine、法国
        • Hôpital Américain de PARIS
      • Nîmes、法国
        • CHU de Nimes
      • Orléans、法国
        • CHR Orleans
      • Osny、法国
        • CHP Sainte-Marie
      • Paris、法国
        • Diaconesses Croix Saint-Simon Hospital Complex
      • Pau、法国
        • Centre hospitalier de Pau
      • Plérin、法国
        • CARIO - Hopital Privé des Cotes d'Armor
      • Poitiers、法国
        • CHU de Poitiers
      • Reims、法国
        • Institut Godinot
      • Rouen、法国
        • Clinique Mathilde - Les Hôpitaux Privés Rouennais
      • Saint-Etienne、法国
        • CHU de Saint-Etienne
      • Saint-Mandé、法国
        • Hia Begin
      • Tours、法国
        • CHU de Tours
      • Vandœuvre-lès-Nancy、法国
        • Institut de Cancérologie de Lorraine
      • Épagny、法国
        • CH Annecy Genevois

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Signed a written informed consent form prior to participate in the study. Note: In case of physical incapacitation, a trusted representative of their choice, which is not the Investigator or sponsor, can sign on the behalf of the patients
  • Patients ≥18 years of age.
  • Patient with histologically documented metastatic triple negative breast cancer (ER (Oestrogen receptor) and PR (Progesterone receptor) <10%, Her2 negative status).
  • Life expectancy > 6 months as per investigator estimate.
  • Patient initiating a marketed authorized first-line systemic treatment in the metastatic setting.
  • Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤2.
  • Patient having completed the EORTC QLQ-C30 and EORTC QLQ-BR45 at baseline (response to questions 29 and 30 of EORTC QLQ-C30 at baseline are mandatory)
  • Affiliated to the social security system or equivalent health insurance.
  • Patient able and willing to complete web-based self-reported questionnaires, from initiation of first-line treatment and for the duration of the study (over multiple treatment lines)
  • Patient has access to a computer, tablet, or smartphone connected to the Internet.

Exclusion Criteria:

  • Participation in another clinical trial using telemonitoring.
  • Physical or psychological incapacity of the patient to use the digital telemonitoring Cureety Techcare, according to the investigator's discretion.
  • Patient deprived of their liberty or under protective custody or guardianship.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:支持治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
无干预:标准护理组
实验性的:Telemonitoring group

Standard of care with digital telemonitoring "Cureety TechCare". The telemonitoring will comprise weekly adverse event (AE) evaluations and their analyses by the "Cureety TechCare".

Each week, patients complete a questionnaire via the Cureety platform, specifically designed for the drug class or specific treatment being administered. Based on their responses, the Cureety TechCare algorithm classifies patients into one of four risk categories: "correct" (green), "compromised" (yellow), "state to be monitored" (orange), or "critical state" (red). (Note: the color code is not visible to the patient).

The medical team uses the dashboard for daily patient monitoring and manages alerts related to the "clinical classification" of the patient's condition. The physician in charge of telemonitoring interprets the data, adjusts the treatment as needed, and provides supportive care during standard care consultations. Patients are also notified of alerts with tailored messages guiding them on the actions to take according to the category determined by the device.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Time to definitive Health-Related Quality of life score Deterioration
大体时间:At baseline then every 3 months, up to 24 months

The time to definitive Health-Related Quality of life score Deterioration is the length of time from randomization to the first deterioration of ≥ 10 points out of 100 or ≥2 points out of 14 in the global health status (GHS) score (items 29 and 30 of the QLQ-C30) compared with the baseline, assuming no improvement of at least 2 points in the GHS score compared with the baseline has occurred.

The responses to the items 29-30 of the QLQ-C30 will be scored using the QLQ scoring manual. These 2 items have possible values ranging from 1 (very bad) to 7 (excellent) corresponding to a sum from 2 to 14 points. After conversion to percentages, the GHS will range from 0% to 100%. The higher the value, the better the quality of life.

At baseline then every 3 months, up to 24 months
Hospitalization-free survival
大体时间:From randomization to death from any cause, up to 24 months

Hospitalization-free survival is the length of time from randomization during which patients enrolled in the study are not hospitalized and remain alive.

From randomization to death from any cause, up to 24 months
Overall survival
大体时间:From randomization to death from any cause, up to 24 months after last inclusion

overall survival is the length of time from randomization during which patients enrolled in the study remain alive.

From randomization to death from any cause, up to 24 months after last inclusion

次要结果测量

结果测量
措施说明
大体时间
Time-to-treatment failure
大体时间:From randomization to treatment discontinuation, up to 24 months

Time-to-treatment failure is the time interval (in months) between the initiation of first-line chemotherapy and its premature discontinuation, irrespective of the reason for discontinuation.

From randomization to treatment discontinuation, up to 24 months
Toxicity-free survival
大体时间:From randomization until the first event, up to 24 months

The National Cancer Institute-Common Terminology Criteria for Adverse Events version 5 (NCI-CTCAE v5) is widely accepted in the oncology research community as the leading rating scale for adverse events. This scale, divided into five grades (1 = "mild," 2 = "moderate," 3 = "severe," 4 = "life-threatening," and 5 = "death") determined by the investigator, will make it possible to assess the severity of the disorders. Toxicity-free survival is defined as the time from randomization to the first event among a grade 3-4 non-hematological adverse event (graded using CTCAE version 5.0), a hospitalization for safety reasons, or death from any cause, whichever occurs first.

From randomization until the first event, up to 24 months
Time to clinical deterioration
大体时间:From randomization, to the date of the first clinical deterioration, up to 24 months

-Time to clinical deterioration is defined by the time between randomization and deterioration of patient's level of functioning determined by the Eastern Cooperative Oncology Group (ECOG) performance status scale. The ECOG, widely accepted in the community of oncology research to assess how the disease affects the daily living abilities of the patient, is composed of 5 levels from grade 0 (fully active, able to carry on all pre-disease performance without restriction) to grade 5 (dead).

From randomization, to the date of the first clinical deterioration, up to 24 months
Number of treatment lines
大体时间:Throughout study completion, up to 24 months

Number of successive treatment lines offered to the patient from randomization to the end of the study.

Throughout study completion, up to 24 months
Incidence of Adverse Events
大体时间:Throughout study completion, up to 24 months

The National Cancer Institute-Common Terminology Criteria for Adverse Events version 5 (NCI-CTCAE v5) is widely accepted in the community of oncology research as the leading rating scale for adverse events. This scale, divided into 5 grades (1 = "mild", 2 = "moderate", 3 = "severe", 4 = "life-threatening", and 5 = "death") determined by the investigator, will make it possible to assess the severity of the disorders.

Throughout study completion, up to 24 months
Quality of life questionnaire - Core 30 (QLQ-C30)
大体时间:At baseline then every 3 weeks, up to 24 months

Developed by the EORTC, this self-reported questionnaire assesses the health-related quality of life of cancer patients in clinical trials.

The questionnaire includes five functional scales (physical, everyday activity, cognitive, emotional, and social), three symptom scales (fatigue, pain, nausea and vomiting), a health/quality of life overall scale, and a number of additional elements assessing common symptoms (including dyspnea, loss of appetite, insomnia, constipation, and diarrhea), as well as, the perceived financial impact of the disease.

All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level.

At baseline then every 3 weeks, up to 24 months
Quality of Life Questionnaire - Breast cancer module (QLQ-BR45)
大体时间:At baseline then every 3 weeks, up to 24 months

This EORTC breast cancer specific questionnaire is intended to supplement the QLQ-C30.

The QLQ-BR45 incorporates nine multi-item scales to assess body image, sexual functioning, breast satisfaction, systemic therapy side effects, arm symptoms, breast symptoms, endocrine therapy symptoms, skin mucosis symptoms, endocrine sexual symptoms. In addition, single items assess sexual enjoyment, future perspective and being upset by hair loss. All items are rated on a four-point Likert-type scale (1 = "not at all", 2 = "a little", 3 = "quite a bit", and 4 = "very much"), and are linearly transformed to a 0-100 scale. Higher scores indicate more severe symptoms or problems for all items.

At baseline then every 3 weeks, up to 24 months
Treatment compliance and extent of exposure
大体时间:Throughout study completion, up to 24 months

The treatment compliance and extent of exposure will be assess using dose intensity, treatment delays and dose reductions.

Throughout study completion, up to 24 months
Compliance with the use of Cureety digital telemonitoring
大体时间:Throughout study completion, up to 24 months

Compliance is measured by the frequency of patient responses to the Cureety telemonitoring questionnaires.

Throughout study completion, up to 24 months
Satisfaction with Cureety telemonitoring
大体时间:3 months after randomisation for the patients and 1 year after the site activation for medical team

Satisfaction with Cureety telemonitoring is measured by the percentage of participants (patients and medical team [including nurse, clinical research associate, and investigators]) satisfied by the regular usage of the Cureety telemonitoring tool.

3 months after randomisation for the patients and 1 year after the site activation for medical team
Patient's global satisfaction with care using the data of the EORTC OUT-PATSAT-35
大体时间:6 months after randomisation

The OUT-PATSAT35 is a 35-item satisfaction with care questionnaire measuring cancer outpatients' perception of hospital doctors and nurses, as well as aspects of care organisation and services. Each item is rated from 1 to 5 (bad to excellent).

6 months after randomisation
Socio-economic impact of digital telemonitoring
大体时间:Throughout study completion, up to 24 months after randomization

Socio-economic impact of digital telemonitoring will be assessed using the number of days of hospitalization and the number of unscheduled hospitalizations and emergency consultations

Throughout study completion, up to 24 months after randomization

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

合作者

调查人员

  • 首席研究员:Jérôme MARTIN-BABAU, MD、Armorican Centre for Radiotherapy, Medical Imaging and Oncology, CARIO, Plérin
  • 首席研究员:Florence JOLY, MD、François Baclesse Center, Caen
  • 首席研究员:Frédéric FITENI, MD、University hospital of Nîmes

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2024年7月25日

初级完成 (实际的)

2025年12月1日

研究完成 (实际的)

2025年12月12日

研究注册日期

首次提交

2024年7月10日

首先提交符合 QC 标准的

2024年7月10日

首次发布 (实际的)

2024年7月17日

研究记录更新

最后更新发布 (实际的)

2026年9月29日

上次提交的符合 QC 标准的更新

2026年9月24日

最后验证

2025年8月1日

更多信息

与本研究相关的术语

其他研究编号

  • UC-BCG-2309
  • IDRCB NUMBER: 2023-A02477-38 (其他标识符:CPP Sud-Méditerranée III)

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

IPD 计划说明

Individual Participant Data will not be shared at an individual level. Those data will be part of the study database including all enrolled patients.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅